These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 39039673)

  • 1. Advances in Understanding and Managing Alzheimer's Disease: From Pathophysiology to Innovative Therapeutic Strategies.
    Rathee S; Sen D; Pandey V; Jain SK
    Curr Drug Targets; 2024; 25(11):752-774. PubMed ID: 39039673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
    Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.
    Shukla D; Suryavanshi A; Bharti SK; Asati V; Mahapatra DK
    Curr Top Med Chem; 2024; 24(19):1699-1737. PubMed ID: 38566385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current pharmacophore based approaches for the development of new anti-Alzheimer's agents.
    Sharma P; Sharma S; Yadav Y; Shukla P; Sagar R
    Bioorg Med Chem; 2024 Nov; 113():117926. PubMed ID: 39306973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Medicinal Chemistry of Memantine Against Alzheimer's Disease.
    Singh YP; Kumar H
    Chem Biol Drug Des; 2024 Oct; 104(4):e14638. PubMed ID: 39370170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.
    Johannesson M; Söderberg L; Zachrisson O; Fritz N; Kylefjord H; Gkanatsiou E; Button E; Svensson AS; Rachalski A; Nygren P; Osswald G; Lannfelt L; Möller C
    Mol Cell Neurosci; 2024 Sep; 130():103949. PubMed ID: 38906341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-modifying drugs in Alzheimer's disease.
    Ghezzi L; Scarpini E; Galimberti D
    Drug Des Devel Ther; 2013 Dec; 7():1471-8. PubMed ID: 24353405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review on Alzheimer's disease pathophysiology and its management: an update.
    Kumar A; Singh A; Ekavali
    Pharmacol Rep; 2015 Apr; 67(2):195-203. PubMed ID: 25712639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation.
    Monteiro KLC; de Aquino TM; da Silva-Júnior EF
    CNS Neurol Disord Drug Targets; 2024; 23(10):1234-1250. PubMed ID: 38018200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
    Brody DL; Jiang H; Wildburger N; Esparza TJ
    Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.